Polyrizon Ltd. (PLRZ)
1.41
-0.04 (-2.76%)
At close: Jan 15, 2025, 11:07 AM
Company Description
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue.
It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza.
The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Polyrizon Ltd.
| Country | IL |
| IPO Date | Oct 29, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Tomer Izraeli |
Contact Details
Address: 5 Ha-Tidhar Street Ra'anana, IL | |
| Website | https://www.polyrizon-biotech.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | IL0011814113 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Tomer Izraeli | Founder, Chief Executive Officer & Director |
| Daphna Avital | Chief People Officer |
| Dr. Eyal S. Ron Ph.D. | Chief Technology Officer |
| Nir Ben Yosef | Chief Financial Officer |
| Dr. Tidhar Turgeman | Chief R&D Officer |